Claims
- 1. A compound of Formula I ##STR11## wherein R.sup.1 is sulfamyl; wherein R.sup.2 is aryl or heterocyclic; wherein R.sup.2 is optionally substituted at a substitutable position with one or more radicals selected from halo, C.sub.1 -C.sub.10 -alkoxy, C.sub.1 -C.sub.20 -alkyl, nitro, C.sub.1 -C.sub.10 -alkylthio, amino, C.sub.1 -C.sub.20 -haloalkyl, hydroxyl, carboxyl, N-mono-C.sub.1 -C.sub.20 -alkylamino, N,N-di-C.sub.1 -C.sub.20 -alkylamino, cyano, C.sub.1 -Clo-alkoxycarbonyl and acylamino;
- wherein R.sup.3 is selected from hydrido, C.sub.1 -C.sub.20 -alkyl, C.sub.1 -C.sub.20 -haloalkyl, cyano, carboxyl, C.sub.1 -C.sub.10 -alkoxycarbonyl, amino, acyl, acylamino, halo and C.sub.1 -C.sub.20 -alkylsulfonylamino; and
- wherein R.sup.4 is aryl or heterocyclic; wherein R.sup.4 is optionally substituted at a substitutable position with one or more radicals selected from halo, C.sub.1 -C.sub.10 -alkoxy, C.sub.1 -C.sub.20 -alkyl, nitro, C.sub.1 -C.sub.10 -alkylthio, amino, C.sub.1 -C.sub.20 -haloalkyl, hydroxyl, carboxyl, N-mono-C.sub.1 -C.sub.20 -alkylamino, N,N-di-C.sub.1 -C.sub.20 -alkylamino, cyano, C.sub.1 -C.sub.10 -alkoxycarbonyl and acylamino;
- provided R.sup.4 cannot be phenyl, 2-thienyl or substituted triazole, when R.sup.3 is hydrido or bromo; further provided R.sup.2 cannot be phenyl, or 2-thienyl, when R.sup.3 is hydrido; and further provided one of R.sup.2 and R.sup.4 is heterocyclic;
- or a pharmaceutically-acceptable salt thereof.
- 2. Compound of claim 1 wherein R.sup.1 is sulfamyl;
- wherein R.sup.2 is aryl or heteroaryl; wherein R.sup.2 is optionally substituted at a substitutable position with one or more radicals selected from halo, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -alkyl, nitro, C.sub.1 -C.sub.6 -alkylthio, amino, C.sub.1 -C.sub.6 -haloalkyl, hydroxyl, carboxyl, N-mono-C.sub.1 -C.sub.20 -alkylamino, N,N-di-C.sub.1 -C.sub.20 -alkylamino, cyano, C.sub.1 -C.sub.10 -alkoxycarbonyl and acylamino;
- wherein R.sup.3 is selected from hydrido, C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -haloalkyl, cyano, carboxyl, C.sub.1 -C.sub.10 -alkoxycarbonyl, amino, acyl, acylamino, halo and C.sub.1 -C.sub.20 -alkylsulfonylamino; and
- wherein R.sup.4 is aryl or heteroaryl; wherein R.sup.4 is optionally substituted at a substitutable position with one or more radicals selected from halo, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -alkyl, nitro, C.sub.1 -C.sub.6 -alkylthio, amino, C.sub.1 -C.sub.6 -haloalkyl, hydroxyl, carboxyl, N-mono-C.sub.1 -C.sub.20 -alkylamino, N,N-di-C.sub.1 -C.sub.20 -alkylamino, cyano, C.sub.1 -C.sub.10 -alkoxycarbonyl and acylamino;
- or a pharmaceutically-acceptable salt thereof.
- 3. Compound of claim 2 wherein R.sup.2 is selected from phenyl, pyrryl, furyl, pyridyl, pyrimidyl, pyrazinyl, pyrazolyl, oxazolyl, isoxazolyl, imidazolyl, thiazyl, pyranyl and thienyl;
- wherein R.sup.2 is optionally substituted at a substitutable position with one or more radicals selected from fluoro, chloro, bromo, iodo, methoxy, ethoxy, propoxy, butoxy, isobutoxy, isopropoxy, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, nitro, methylthio, ethylthio, amino, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, hydroxyl, carboxyl, N-methylamino, N-ethylamino, N-isopropylamino, N-propylamino, N-butylamino, N-isobutylamino, N-tert-butylamino, N-pentylamino, N,N-dimethylamino, N-methyl-N-ethylamino, cyano, methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, tert-butoxycarbonyl, propoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, pentoxycarbonyl and acetamido;
- wherein R.sup.3 is selected from hydrido, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, cyano, carboxyl, methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, tert-butoxycarbonyl, propoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, pentoxycarbonyl, amino, acetyl, formyl, acetamido, fluoro, chloro, iodo, bromo and CH.sub.3 SO.sub.2 NH--; and
- wherein R.sup.4 is selected from phenyl, pyrryl, furyl, pyridyl, pyrimidyl, pyrazinyl, pyrazolyl, oxazolyl, isoxazolyl, imidazolyl, thiazyl, pyranyl and thienyl; wherein R.sup.4 is optionally substituted at a substitutable position with one or more radicals selected from fluoro, chloro, bromo, iodo, methoxy, ethoxy, propoxy, butoxy, isobutoxy, isopropoxy, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, nitro, methylthio, ethylthio, amino, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, hydroxyl, carboxyl, N-methylamino, N-ethylamino, N-isopropylamino, N-propylamino, N-butylamino, N-isobutylamino, N-tert-butylamino, N-pentylamino, N,N-dimethylamino, N-methyl-N-ethylamino, cyano, methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, tert-butoxycarbonyl, propoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, pentoxycarbonyl and acetamido;
- or a pharmaceutically-acceptable salt thereof.
- 4. Compound of claim 3 selected from compounds, and their pharmaceutically-acceptable salts, of the group of compounds consisting of
- 4-�3-(4-pyridyl)-5-(4-chlorophenyl)-1H-pyrazol-1-yl!benzenesulfonamide;
- 4-�3-(2-thienyl)-5-(4-chlorophenyl)-1H-pyrazol-1-yl!benzenesulfonamide;
- 4-�3-(5-chloro-2-thienyl)-5-(4-chlorophenyl)-1H-pyrazol-1-yl!benzenesulfonamide;
- 4-�3-(2-furanyl)-5-(4-chlorophenyl)-1H-pyrazol-1-yl!benzenesulfonamide;
- 4-�3-(4-chlorophenyl)-5-(2-thienyl)-1H-pyrazol-1-yl!benzenesulfonamide;
- 4-�3-(4-chlorophenyl)-5-(4-pyridyl)-1H-pyrazol-1-yl!benzenesulfonamide; and
- 4-�3-(4-chlorophenyl)-5-(2-furanyl)-1H-pyrazol-1-yl!benzenesulfonamide.
- 5. A pharmaceutical composition comprising a therapeutically-effective amount of a compound and a pharmaceutically-acceptable carrier or diluent, said compound selected from a family of compounds of Formula I ##STR12## wherein R.sup.1 is sulfamyl; wherein R.sup.2 is aryl or heterocyclic; wherein R.sup.2 is optionally substituted at a substitutable position with one or more radicals selected from halo, C.sub.1 -c.sub.10 -alkoxy, C.sub.1 -C.sub.20 -alkyl, nitro, C.sub.1 -C.sub.10 -alkylthio, amino, C.sub.1 -C.sub.20 -haloalkyl, hydroxyl, carboxyl, N-mono-C.sub.1 -C.sub.20 -alkylamino, N,N-di-C.sub.1 -C.sub.20 -alkylamino, cyano, C.sub.1 -C.sub.10 -alkoxycarbonyl and acylamino;
- wherein R.sup.3 is selected from hydrido, C.sub.1 -C.sub.20 -alkyl, C.sub.1 -C.sub.20 -haloalkyl, cyano, carboxyl, C.sub.1 -C.sub.10 -alkoxycarbonyl, amino, acyl, acylamino, halo and C.sub.1 -C.sub.20 -alkylsulfonylamino; and
- wherein R.sup.4 is aryl or heterocyclic; wherein R.sup.4 is optionally substituted at a substitutable position with one or more radicals selected from halo, C.sub.1 -C.sub.10 -alkoxy, C.sub.1 -C.sub.20 -alkyl, nitro, C.sub.1 -C.sub.10 -alkylthio, amino, C.sub.1 -C.sub.20 -haloalkyl, hydroxyl, carboxyl, N-mono-C.sub.1 -C.sub.20 -alkylamino, N,N-di-C.sub.1 -C.sub.20 -alkylamino, cyano, C.sub.1 -C.sub.10 -alkoxycarbonyl and acylamino;
- provided R.sup.4 cannot be phenyl, 2-thienyl or substituted triazole, when R.sup.3 is hydrido or bromo; further provided R.sup.2 cannot be phenyl, or 2-thienyl, when R.sup.3 is hydrido; and further provided one of R.sup.2 and R.sup.4 is heterocyclic;
- or a pharmaceutically-acceptable salt thereof.
- 6. The composition of claim 5 wherein R.sup.1 is sulfamyl;
- wherein R.sup.2 is aryl or heteroaryl; wherein R.sup.2 is optionally substituted at a substitutable position with one or more radicals selected from halo, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -alkyl, nitro, C.sub.1 -C.sub.6 -alkylthio, amino, C.sub.1 -C.sub.6 -haloalkyl, hydroxyl, carboxyl, N-mono-C.sub.1 -C.sub.20 -alkylamino, N,N-di-C.sub.1 -C.sub.20 -alkylamino, cyano, C.sub.1 -C.sub.10 -alkoxycarbonyl and acylamino;
- wherein R.sup.3 is selected from hydrido, C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -haloalkyl, cyano, carboxyl, C.sub.1 -C.sub.10 -alkoxycarbonyl, amino, acyl, acylamino, halo and C.sub.1 -C.sub.20 -alkylsulfonylamino; and
- wherein R.sup.4 is aryl or heteroaryl; wherein R.sup.4 is optionally substituted at a substitutable position with one or more radicals selected from halo, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -alkyl, nitro, C.sub.1 -C.sub.6 -alkylthio, amino, C.sub.1 -C.sub.6 -haloalkyl, hydroxyl, carboxyl, N-mono-C.sub.1 -C.sub.20 -alkylamino, N,N-di-C.sub.1 -C.sub.20 -alkylamino, cyano, C.sub.1 -C.sub.10 -alkoxycarbonyl and acylamino;
- or a pharmaceutically-acceptable salt thereof.
- 7. The composition of claim 6 wherein R.sup.2 is selected from phenyl, pyrryl, furyl, pyridyl, pyrimidyl, pyrazinyl, pyrazolyl, oxazolyl, isoxazolyl, imidazolyl, thiazyl, pyranyl and thienyl;
- wherein R.sup.2 is optionally substituted at a substitutable position with one or more radicals selected from fluoro, chloro, bromo, iodo, methoxy, ethoxy, propoxy, butoxy, isobutoxy, isopropoxy, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, nitro, methylthio, ethylthio, amino, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, hydroxyl, carboxyl, N-methylamino, N-ethylamino, N-isopropylamino, N-propylamino, N-butylamino, N-isobutylamino, N-tert-butylamino, N-pentylamino, N,N-dimethylamino, N-methyl-N-ethylamino, cyano, methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, tert-butoxycarbonyl, propoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, pentoxycarbonyl and acetamido;
- wherein R.sup.3 is selected from hydrido, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, cyano, carboxyl, methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, tert-butoxycarbonyl, propoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, pentoxycarbonyl, amino, acetyl, formyl, acetamido, fluoro, chloro, iodo, bromo and CH.sub.3 SO.sub.2 NH--;
- wherein R.sup.4 is selected from phenyl, pyrryl, furyl, pyridyl, pyrimidyl, pyrazinyl, pyrazolyl, oxazolyl, isoxazolyl, imidazolyl, thiazyl, pyranyl and thienyl;
- wherein R.sup.4 is optionally substituted at a substitutable position with one or more radicals selected from fluoro, chloro, bromo, iodo, methoxy, ethoxy, propoxy, butoxy, isobutoxy, isopropoxy, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, nitro, methylthio, ethylthio, amino, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, hydroxyl, carboxyl, N-methylamino, N-ethylamino, N-isopropylamino, N-propylamino, N-butylamino, N-isobutylamino, N-tert-butylamino, N-pentylamino, N,N-dimethylamino, N-methyl-N-ethylamino, cyano, methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, tert-butoxycarbonyl, propoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, pentoxycarbonyl and acetamido;
- or a pharmaceutically-acceptable salt thereof.
- 8. The composition of claim 7 wherein said compound is selected from compounds, and their pharmaceutically-acceptable salts, of the group consisting of
- 4-�3,5-bis(4-chlorophenyl)-1H-pyrazol-1-4-�3-(4-pyridyl)-5-(4-chlorophenyl)-1H-pyrazol-1-yl!benzenesulfonamide;
- 4-�3-(2-thienyl)-5-(4-chlorophenyl)-1H-pyrazol-1-yl!benzenesulfonamide;
- 4-�3-(5-chloro-2-thienyl)-5-(4-chlorophenyl)-1H-pyrazol-1-yl!benzenesulfonamide;
- 4-�3-(2-furanyl)-5-(4-chlorophenyl)-1H-pyrazol-1-yl!benzenesulfonamide;
- 4-�3-(4-chlorophenyl)-5-(2-thienyl)-1H-pyrazol-1-yl!benzenesulfonamide;
- 4-�3-(4-chlorophenyl)-5-(4-pyridyl)-1H-pyrazol-1-yl!benzenesulfonamide; and
- 4-�3-(4-chlorophenyl)-5-(2-furanyl)-1H-pyrazol-1-yl!benzenesulfonamide.
- 9. A therapeutic method of treating inflammation or an inflammation-related disorder in a subject, said method comprising administering to the subject having or susceptible to such inflammation or inflammation-related disorder, a therapeutically-effective amount of a compound of Formula I ##STR13## wherein R.sup.1 is sulfamyl; wherein R.sup.2 is aryl or heterocyclic; wherein R.sup.2 is optionally substituted at a substitutable position with one or more radicals selected from halo, C.sub.1 -C.sub.10 -alkoxy, C.sub.1 -C.sub.20 -alkyl, nitro, C.sub.1 -C.sub.10 -alkylthio, amino, C.sub.1 -C.sub.20 -haloalkyl, hydroxyl, carboxyl, N-mono-C.sub.1 -C.sub.20 -alkylamino, N,N-di-C.sub.1 -C.sub.20 -alkylamino, cyano, C.sub.1 -C.sub.10 -alkoxycarbonyl and acylamino;
- wherein R.sup.3 is selected from hydrido, C.sub.1 -C.sub.20 -alkyl, C.sub.1 -C.sub.20 -haloalkyl, cyano, carboxyl, C.sub.1 -C.sub.10 -alkoxycarbonyl, amino, acyl, acylamino, halo and C.sub.1 -C.sub.20 -alkylsulfonylamino; and
- wherein R.sup.4 is aryl or heterocyclic; wherein R.sup.4 is optionally substituted at a substitutable position with one or more radicals selected from halo, C.sub.1 -C.sub.10 -alkoxy, C.sub.1 -C.sub.20 -alkyl, nitro, C.sub.1 -C.sub.10 -alkylthio, amino, C.sub.1 -C.sub.20 -haloalkyl, hydroxyl, carboxyl, N-mono-C.sub.1 -C.sub.20 -alkylamino, N,N-di-C.sub.1 -C.sub.20 -alkylamino, cyano, C.sub.1 -C .sub.10 -alkoxycarbonyl and acylamino;
- provided one of R.sup.2 and R.sup.4 is heterocyclic;
- or a pharmaceutically-acceptable salt thereof.
- 10. The method of claim 9 wherein R.sup.1 is sulfamyl; wherein R.sup.2 is aryl or heteroaryl; wherein R.sup.2 is optionally substituted at a substitutable position with one or more radicals selected from halo, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -alkyl, nitro, C.sub.1 -C.sub.6 -alkylthio, amino, C.sub.1 -C.sub.6 -haloalkyl, hydroxyl, carboxyl, N-mono-C.sub.1 -C.sub.20 -alkylamino, N,N-di-C.sub.1 -C.sub.20 -alkylamino, cyano, C.sub.1 -C.sub.10 -alkoxycarbonyl and acylamino;
- wherein R.sup.3 is selected from hydrido, C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -haloalkyl, cyano, carboxyl, C.sub.1 -C.sub.10 -alkoxycarbonyl, amino, acyl, acylamino, halo and C.sub.1 -C.sub.20 -alkylsulfonylamino; and
- wherein R.sup.4 is aryl or heteroaryl; wherein R.sup.4 is optionally substituted at a substitutable position with one or more radicals selected from halo, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -alkyl, nitro, C.sub.1 -C.sub.6 -alkylthio, amino, C.sub.1 -C.sub.6 -haloalkyl, hydroxyl, carboxyl, N-mono-C.sub.1 -C.sub.20 -alkylamino, N,N-di-C.sub.1 -C.sub.20 -alkylamino, cyano, C.sub.1 -C.sub.10 -alkoxycarbonyl and acylamino;
- or a pharmaceutically-acceptable salt thereof.
- 11. The method of claim 9 wherein R.sup.2 is selected from phenyl, pyrryl, furyl, pyridyl, pyrimidyl, pyrazinyl, pyrazolyl, oxazolyl, isoxazolyl, imidazolyl, thiazyl, pyranyl and thienyl; wherein R.sup.2 is optionally substituted at a substitutable position with one or more radicals selected from fluoro, chloro, bromo, iodo, methoxy, ethoxy, propoxy, butoxy, isobutoxy, isopropoxy, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, nitro, methylthio, ethylthio, amino, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, hydroxyl, carboxyl, N-methylamino, N-ethylamino, N-isopropylamino, N-propylamino, N-butylamino, N-isobutylamino, N-tert-butylamino, N-pentylamino, N,N-dimethylamino, N-methyl-N-ethylamino, cyano, methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, tert-butoxycarbonyl, propoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, pentoxycarbonyl and acetamido; wherein R.sup.3 is selected from hydrido, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, cyano, carboxyl, methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, tert-butoxycarbonyl, propoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, pentoxycarbonyl, amino, acetyl, formyl, acetamido, fluoro, chloro, iodo, bromo and CH.sub.3 SO.sub.2 NH--; and wherein R.sup.4 is selected from phenyl, pyrryl, furyl, pyridyl, pyrimidyl, pyrazinyl, pyrazolyl, oxazolyl, isoxazolyl, imidazolyl, thiazyl, pyranyl and thienyl; wherein R.sup.4 is optionally substituted at a substitutable position with one or more radicals selected from fluoro, chloro, bromo, iodo, methoxy, ethoxy, propoxy, butoxy, isobutoxy, isopropoxy, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, nitro, methylthio, ethylthio, amino, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, hydroxyl, carboxyl, N-methylamino, N-ethylamino, N-isopropylamino, N-propylamino, N-butylamino, N-isobutylamino, N-tert-butylamino, N-pentylamino, N,N-dimethylamino, N-methyl-N-ethylamino, cyano, methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, tert-butoxycarbonyl, propoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, pentoxycarbonyl and acetamido; or a pharmaceutically-acceptable salt thereof.
- 12. The method of claim 9 wherein said compound is selected from compounds, and their pharmaceutically-acceptable salts, of the group consisting of
- 4-�3-(4-pyridyl)-5-(4-chlorophenyl)-1H-pyrazol-1-yl!benzenesulfonamide;
- 4-�3-(2-thienyl)-5-(4-chlorophenyl)-1H-pyrazol-1-yl!benzenesulfonamide;
- 4-�3-(5-chloro-2-thienyl)-5-(4-chlorophenyl)-1H-pyrazol-1-yl!benzenesulfonamide;
- 4-�3-(2-furanyl)-5-(4-chlorophenyl)-1H-pyrazol-1-yl!benzenesulfonamide;
- 4-�3-(4-chlorophenyl)-5-(2-thienyl)-1H-pyrazol-1-yl!benzenesulfonamide;
- 4-�3-(4-chlorophenyl)-5-(4-pyridyl)-1H-pyrazol-1-yl!benzenesulfonamide; and
- 4-�3-(4-chlorophenyl)-5-(2-furanyl)-1H-pyrazol-1-yl!benzenesulfonamide.
- 13. The method of claim 9 for use in treatment of inflammation.
- 14. The method of claim 9 for use in treatment of an inflammation-associated disorder.
- 15. The method of claim 14 wherein the inflammation-associated disorder is arthritis.
- 16. The method of claim 14 wherein the inflammation-associated disorder is pain.
- 17. The method of claim 14 wherein the inflammation-associated disorder is fever.
RELATED CASES
This is an application under 35 USC .sctn.371 of International Application PCT/US94/12722, with an international filing date of November 14, 1994, which is a continuation-in-part of U.S. patent application Ser. No. 08/160,517, filed Nov. 30, 1993, now issued as U.S. Pat. No. 5,434,178.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/US94/12722 |
11/14/1994 |
|
|
5/30/1996 |
5/30/1996 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO95/15318 |
6/8/1995 |
|
|
US Referenced Citations (7)
Non-Patent Literature Citations (7)
Entry |
H. Faidallah et al, Pak. J. Sci. Ind. Res., 35, 213 (1992). |
H. Mokhtar et al, Pak. J. Sci. Ind. Res., 35, 428 (1992). |
H. Faid-Allah et al, Ind. J. Chem., 27B, 245 (1988). |
R. Soliman et al, J. Pharm. Sci., 76, 626 (1987). |
H. Faidallal et al, Pak. J. Sci. Ind. Res., 35, 8 (1992). |
R. Soliman et al, J. Pharm. Sci., 70, 606 (1981). |
Chemical Abstracts, 121:11 (1994). |
Continuations (1)
|
Number |
Date |
Country |
Parent |
160517 |
|
|